- Author January 2023
- Category eNews
- DATE 25 Jan 2023
Australia New Zealand Gynaecological Oncology Group
ANZGOG 2023 Annual Scientific Meeting
ANZGOG’s 2023 Annual Scientific Meeting will be held 22-24 March 2023 at the Hilton Hotel, Brisbane Queensland. “Improving the lived experience of patients with gynaecological cancers” is the theme for the meeting.
We will review the key advances over the last 5-10 years in gynaecological cancers that have defined new standards of care, improved survival and quality of life. Major challenges remain in optimising patient care and meeting the needs of all patients, including culturally diverse and marginalised populations. We can and will rise to the challenge.
We are pleased to announce our distinguished international speakers: Prof Iain McNeish, Prof Rene Pareja and Dr Ina Jürgenliemk-Schulz.
ANZGOG’s Annual Scientific Meeting brings together national and international experts in gynaecological medicine, radiation and surgical oncology, pathology, basic scientists, translational and quality of life researchers, study coordinators and nurses, as well as our partners in the pharmaceutical industry.
The meeting enables attendees to learn about the latest developments in gynaecological cancer and provides education and capacity-building opportunities amongst members and industry personnel. The Pure Science Symposium is the forum for scientists to learn about the cutting-edge research and developments in the pre-clinical and translational space.
Earlybird closes on Wednesday, 1 February 2023, so register now to secure your space. For more information, please visit www.anzgogasm.org.au
We look forward to seeing you in Brisbane for a rich and stimulating conference.
Powering research development
ANZGOG continues to expand its trials in operation, in development and in the pipeline. We are fortunate to have 1200 dedicated members working locally and globally to improve life for women affected by gynaecological cancer through research.
We were delighted to be able to open three studies to recruitment this year – HyNOVA, ADELE and PARAGON-II. On the other end of the trial cycle, seven studies closed to recruitment after meeting significant recruitment milestones:
- The international AtTEnd trial, led by ANZGOG in ANZ, reached its recruitment target of 550 participants, including 48 participants from ANZ.
- TIPS, an ovarian cancer surgical feasibility study, reached 100% recruitment after successfully recruiting its target of 47 patients.
- ICON9, an international phase III randomised study, recruited a total of 111 patients (ANZ target was 110).
- SOLACE2, an ovarian cancer study part of the OASIS Initiative, also reached 100% recruitment, recruiting 114 women across Australia.
We thank all participating women and their families, participating hospitals and collaborating trial teams for their long-term commitment to the studies.
ANZGOG trial update
ANZGOG clinical trials open to recruitment:
- 2 ovarian cancer trials: ECHO and HyNOVA in collaboration with the NHRMC Clinical trials Centre, at the University of Sydney
- 2 endometrial cancer trials: ENDO-3 in collaboration with Queensland Centre for Gynaecological Cancer and ADELE in collaboration with the NHRMC Clinical trials Centre, at the University of Sydney
- 1 ovarian and endometrial cancer trial: PARAGON II in collaboration with NHMRC Clinical Trials Centre, at the University of Sydney
ANZGOG clinical trials in start-up:
- 1 ovarian and endometrial cancer trial: EPOCH
- 1 cervical cancer trial: ITTACc
- 1 Quality of Live/End of life study: PEACE
For more information on ANZGOG’s trials, please visit our website.
Join Australia's leading oncology community & make an impact
Become a COSA memberTwitter
@COSAoncology
Follow
COSAoncology 14 hours ago
Join COSA, the national multidisciplinary community for health care professionals working in cancer care. Get involved and make a difference in cancer care through collaboration, research, advocacy and education: https://t.co/KyH4eMpIOp https://t.co/GshP848w1h
Read More >COSAoncology yesterday
RT @ACSC_PeterMac: Calling all clinicians interested in survivorship care for #cancersurvivors with treatable but not curable cancers. Regi…
Read More >COSAoncology yesterday
COSA's March eNews is in members' inboxes now ... ... or available to COSA members at https://t.co/DCJYUXIxl3 https://t.co/FW6f8nIXMg
Read More >COSAoncology 2 days ago
COSA is the national oncology community bringing together multidisciplinary health professionals across all cancers to advance care and improve outcomes. More on member benefits here: https://t.co/4Fw9lbNDrf https://t.co/EGBDBenLQp
Read More >COSAoncology 4 days ago
It only takes a few minutes to join COSA – Plus, join before 30 April 2024 and not only get bonus months of membership, but also save on member rates before prices increase for 2024! Join now: https://t.co/KyH4eMpIOp https://t.co/KuSX6hoRdv
Read More >COSAoncology 8 days ago
Make the most of your COSA membership savings! A discount applies if you’re a member of an Affiliated or Associated organisation. Plus - join before 30 April 2024 to get a saving on member rates before they increase for 2024. https://t.co/szOpiPmIr7 https://t.co/9bcc678y2C
Read More >COSAoncology 8 days ago
2023 was quite a year! COSA members will find the COSA Annual Report 2023 in their inboxes; everyone else can find it at https://t.co/a88OK0m92Z Contains reports from 36 COSA Groups and Affiliate Organisations, as well as overviews from the President, CEO and 2023 ASM Convenor. https://t.co/C1wQQLJQT7
Read More >COSAoncology 9 days ago
RT @LaceyJudith: National Symposium, few places left register now! @COSAoncology @COSA_Surviv @ABigaranAEP @davemiz_EP @DrNicolasHart @drc…
Read More >COSAoncology 10 days ago
RT @M_Jefford: Our correspondence, #OpenAccess in @JCO_ASCO today 🚨 shared care for #cancersurvivors is preferred by pts, cheaper for the h…
Read More >COSAoncology 10 days ago
RT @cancer_K2A: Another big day of great presentations at #WICC2024 If you’re interested in learning how #survonc & supportive care can im…
Read More >